Bedrijfsoverzicht
NewGenIvf Group Limited is an investment holding company that specializes in providing assisted reproductive services to couples and individuals seeking fertility treatments across Thailand, Cambodia, Hong Kong, and Kyrgyzstan. Operating within the broader healthcare sector and specifically the medical care facilities industry, the company delivers a comprehensive range of fertility treatment solutions, including in vitro fertilization. As of the latest data, the company maintains a market capitalization of $1.16M and employs a workforce of 87 individuals to support its operational scope. The reported annual revenue of $4.73M indicates a relatively small market footprint, suggesting that the company functions as a niche player rather than a dominant force in the global fertility treatment market. These valuation and revenue figures collectively illustrate a business that has secured a specific operational presence but remains a minor entity within the substantial healthcare infrastructure.
Financiële gezondheid
The financial statements for the trailing twelve months reveal a revenue of $4.73M and a net income of $9.88M, while EBITDA stands at $-10,538,352. The significant divergence between the positive net income and the negative EBITDA reveals a highly unconventional cost structure where non-operating income or gains likely contribute substantially to the bottom line, masking the underlying operational cash burn. Free cash flow for the period is recorded at $-10,464,332, indicating that the company is currently consuming cash rather than generating it, which limits its immediate financial flexibility and ability to fund internal expansion without external capital. The company reports a gross margin of 20.2%, an operating margin of -349.1%, and a profit margin of 209.0%; the negative operating margin suggests that operating expenses vastly exceed operating revenue, while the positive profit margin highlights the impact of non-operating factors on the final earnings. On the balance sheet, cash holdings of $958,556 fall significantly short of the total debt obligation of $4.87M, and the debt-to-equity ratio of 18.74 indicates a highly leveraged financial position. Despite the high leverage, the current ratio of 3.12 suggests that the company possesses sufficient current assets to cover its short-term liabilities, providing a degree of liquidity buffer despite the debt burden. Return on Equity is calculated at 79.4% while Return on Assets is -36.9%, metrics that reveal management is generating significant accounting returns on equity, likely driven by the aforementioned non-operating gains, while simultaneously failing to generate returns on the asset base used to support operations.
Waarderingsbeoordeling
Valuation metrics for NewGenIvf Group Limited show a trailing P/E ratio of 0.06 and a forward P/E of 0.22, a discrepancy that implies the market expects earnings to remain negligible or volatile in the near term rather than anticipating a standard earnings trajectory. The price-to-book ratio is recorded at 0.02, indicating that the market values the company at a fraction of its book value, which suggests a deep discount or significant concerns regarding the sustainability of its asset base. Alternative valuation metrics such as the price-to-sales ratio of 0.25 and an EV/EBITDA of -0.42 further underscore the difficulty in applying traditional multiples to this entity, as the negative EV/EBITDA reflects the substantial EBITDA loss relative to enterprise value. Price metrics show a 52-week high of $1839.00 and a 52-week low of $1.52, placing the current trading price significantly below the historical high and reflecting extreme volatility in the stock's recent performance history. The beta value of 0.09 indicates that the stock exhibits extremely low price volatility relative to the broader market, behaving almost like a risk-free asset in terms of price movement despite its financial characteristics.
Growth & Income
Revenue growth year-over-year is recorded at 11.9%, whereas earnings growth is marked as N/A, preventing a direct comparison of earnings velocity against revenue expansion. The absence of reported earnings growth data precludes a definitive statement on whether earnings are growing faster or slower than revenue, but the revenue increase suggests top-line momentum despite the financial complexities noted earlier. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests all available accounting earnings back into the business or retains them rather than distributing them to shareholders. This reinvestment strategy is consistent with companies that prioritize capital allocation for growth or survival over income distribution, though the specific use of funds is not detailed in the available facts. The overall growth and income profile is characterized by positive revenue expansion, a complete absence of dividend income, and a reliance on accounting earnings that differ significantly from operational cash flow metrics.